Scholarlink

<p>Sepsis-related myocardial injury (SRMI) is a major contributor to mortality in septic patients, driven by uncontrolled inflammation and macrophage dysregulation. Bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos) possess immunomodulatory properties, but their cardioprotective mechanisms remain unclear. Here, we investigated whether BMSC-Exos deliver microRNA-143-3p (miR-143-3p) to reprogram macrophages and attenuate SRMI. Exosomes were isolated from murine bone marrow mesenchymal stem cells and characterized by electron microscopy, nanoparticle tracking analysis, and immunoblotting. In lipopolysaccharide-stimulated macrophages, BMSC-Exos promoted a shift from pro-inflammatory M1 to reparative M2 polarization, and reduced pro-inflammatory cytokine secretion. In a mouse model of endotoxemia, BMSC-Exo administration improved seven-day survival, preserved cardiac function, decreased circulating myocardial injury markers, and increased the proportion of cardiac M2 macrophages. MicroRNA sequencing identified miR-143-3p as highly enriched in BMSC-Exos but downregulated in circulating exosomes from septic mice. Delivery of miR-143-3p mimics recapitulated the protective effects of BMSC-Exos, while inhibition of miR-143-3p exacerbated injury. Mechanistically, miR-143-3p directly targeted Toll-like receptor 4 (TLR4) and suppressed the downstream myeloid differentiation primary response 88/nuclear factor-κB (MyD88/NF-κB) signaling pathway. Furthermore, TLR4 knockdown phenocopied the anti-inflammatory and M2-polarizing effects of miR-143-3p. These findings indicate that BMSC-Exos attenuate SRMI by transferring miR-143-3p to macrophages, where it inhibits TLR4/MyD88/NF-κB signaling and promotes M2 polarization, highlighting a potential therapeutic strategy for septic cardiac injury.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic Delivery of Bone Marrow Mesenchymal Stem Cell-Derived Exosomal miR-143-3p Inhibits Myocardial and Systemic Inflammation and Attenuates Sepsis-Related Myocardial Injury

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月10日

查看全文
  • Yuyang Qiu,
  • Lian Liao,
  • Tian Zhang,
  • Yiming Ma,
  • Jianyu Fu,
  • Jiakai Wang,
  • Xu Liu,
  • Wei Xie

摘要

Sepsis-related myocardial injury (SRMI) is a major contributor to mortality in septic patients, driven by uncontrolled inflammation and macrophage dysregulation. Bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos) possess immunomodulatory properties, but their cardioprotective mechanisms remain unclear. Here, we investigated whether BMSC-Exos deliver microRNA-143-3p (miR-143-3p) to reprogram macrophages and attenuate SRMI. Exosomes were isolated from murine bone marrow mesenchymal stem cells and characterized by electron microscopy, nanoparticle tracking analysis, and immunoblotting. In lipopolysaccharide-stimulated macrophages, BMSC-Exos promoted a shift from pro-inflammatory M1 to reparative M2 polarization, and reduced pro-inflammatory cytokine secretion. In a mouse model of endotoxemia, BMSC-Exo administration improved seven-day survival, preserved cardiac function, decreased circulating myocardial injury markers, and increased the proportion of cardiac M2 macrophages. MicroRNA sequencing identified miR-143-3p as highly enriched in BMSC-Exos but downregulated in circulating exosomes from septic mice. Delivery of miR-143-3p mimics recapitulated the protective effects of BMSC-Exos, while inhibition of miR-143-3p exacerbated injury. Mechanistically, miR-143-3p directly targeted Toll-like receptor 4 (TLR4) and suppressed the downstream myeloid differentiation primary response 88/nuclear factor-κB (MyD88/NF-κB) signaling pathway. Furthermore, TLR4 knockdown phenocopied the anti-inflammatory and M2-polarizing effects of miR-143-3p. These findings indicate that BMSC-Exos attenuate SRMI by transferring miR-143-3p to macrophages, where it inhibits TLR4/MyD88/NF-κB signaling and promotes M2 polarization, highlighting a potential therapeutic strategy for septic cardiac injury.